ZimVie (NASDAQ:ZIMV – Get Free Report) issued an update on its FY 2024 earnings guidance on Thursday morning. The company provided earnings per share (EPS) guidance of 0.550-0.700 for the period, compared to the consensus estimate of 0.590. The company issued revenue guidance of $450.0 million-$460.0 million, compared to the consensus revenue estimate of $453.9 million.
Wall Street Analyst Weigh In
Separately, Needham & Company LLC lifted their price objective on ZimVie from $20.00 to $23.00 and gave the stock a buy rating in a report on Friday.
Get Our Latest Analysis on ZimVie
ZimVie Price Performance
ZimVie (NASDAQ:ZIMV – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported $0.13 earnings per share (EPS) for the quarter. ZimVie had a positive return on equity of 2.09% and a negative net margin of 63.84%. The business had revenue of $116.81 million for the quarter. During the same period in the previous year, the firm earned $0.17 EPS. On average, equities research analysts predict that ZimVie will post 0.63 EPS for the current fiscal year.
ZimVie Company Profile
ZimVie Inc, together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to treat various spine pathologies, and support dental tooth replacement and restoration procedures worldwide. It operates through two segments, The Dental Segment and The Spine Segment.
Read More
- Five stocks we like better than ZimVie
- The How And Why of Investing in Oil Stocks
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Stock Dividend Cuts Happen Are You Ready?
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Find Undervalued Stocks
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for ZimVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZimVie and related companies with MarketBeat.com's FREE daily email newsletter.